Sisram Medical reports mixed H1 2025 results; international markets show resilience

Sisram Medical reported total revenue of $165.5 million for the first half of 2025, a 1.9% decrease from $168.7 million in 2024. This was primarily attributed to challenging market conditions in North America, which was largely offset by a 7.1% revenue growth in international markets outside North America. Gross profit amounted to $99.3 million, a 5.7% decrease, with the gross profit margin falling to 60.0% from 62.4% in 2024 due to product mix shifts and increased component costs.

Profit before tax for the period decreased by 19.9% to $11.8 million, and profit for the period dropped by 31.9% to $9.0 million. The adjusted net profit was $12.0 million, representing a 28.1% decrease, with an adjusted net profit margin of 7.2%. The company's injectables segment saw significant growth, with revenue increasing by 218.1% to $14.4 million, while medical aesthetics revenue decreased by 7.8% to $137.7 million.

Looking ahead, Sisram Medical forecasts stronger performance in H2 2025. This is expected to be driven by sustained consumer confidence, rising market demand, and the anticipated launch of DAXXIFY in Mainland China. The company also plans to accelerate the market ramp-up of its new energy-based devices and expand its injectable portfolio in key regions like the UK, Australia, and Thailand.